Arexvy

Generic name: Respiratory Syncytial Virus Vaccine, Adjuvanted (rsv Vaccine Pref3, Recombinant Systemic)
Dosage form: suspension for intramuscular injection
Drug class: Viral vaccines

Usage of Arexvy

Arexvy is a vaccination against the respiratory syncytial virus (RSV) that may be used to protect adults aged 60 years and older against lower respiratory tract disease (LRTD) caused by RSV.

RSV is a common, contagious virus that can cause hospitalization and death, especially in older adults with underlying medical conditions such as diabetes and chronic heart and lung diseases. The vaccine showed 94.6% efficacy in reducing the risk of developing RSV-associated LRTD in older adults with underlying conditions, with an overall efficacy of 82.6%.

Arexvy works by inducing an immune response against the RSVpreF3 antigen, the main protein found on the surface of RSV.

Arexvy was approved on May 3, 2023, and it was the first RSV vaccine to be approved for older adults.

Arexvy side effects

Arexvy is generally well tolerated and the most common side effects include:

  • Injection site pain (61%)
  • Fatigue (tiredness) (34%)
  • Muscle aches (29%)
  • Headache (27%)
  • Joint pain (18%).

    • Side effects are generally temporary and do not last long.

    Relate drugs

    How to use Arexvy

    Arexvy is given by intramuscular injection, usually into the deltoid muscle of the upper arm.

    The dose is 0.5mL.

    Warnings

    Anaphylaxis

    Possible anaphylactic reactions may occur. Do not administer Arexvy to anyone with a known history of a severe allergic reaction to it or any of its components. Always administer in a facility that can provide the appropriate medical treatment and supervision to manage possible anaphylactic reactions following administration.

    Syncope (fainting)

    Fainting may occur following the administration of vaccines. Procedures should be in place to avoid injury from fainting.

    Immunosuppression

    People who are immunocompromised, including those receiving immunosuppressive therapy, may have a diminished immune response to Arexvy.

    Other adults, pregnancy, or lactation

    Arexvy is not approved for use in persons <60 years of age. It is not approved for use in pregnant or breastfeeding women.

    Children

    Arexvy is not approved for use in children.

    Popular FAQ

    Arexvy is not a live vaccine it is a recombinant subunit vaccine that does not contain any live virus. Recombinant vaccines are made by taking a small piece of DNA that codes for a specific protein (called an antigen) on the virus (in this case the respiratory syncytial virus [RSV]) and inserted into bacteria or yeast cells in a laboratory to manufacture the vaccine. The vaccine helps your body's immune system make proteins called antibodies against the virus. These antibodies will help prevent infection by attacking the virus if it ever infects your body.

    Arexvy is an adjuvanted recombinant subunit vaccine. To break this down: Adjuvanted – This means it contains a substance that helps to enhance the effects of the vaccine by boosting the response of the immune system Recombinant subunit – This means it is made by taking a small piece of DNA that codes for a specific protein (called an antigen) on the virus (in this case the respiratory syncytial virus [RSV]) and inserting it into bacteria or yeast cells in a laboratory to manufacture the vaccine. The vaccine helps your body's immune system make proteins called antibodies against the virus. These antibodies will help prevent infection by attacking the virus if it ever infects your body.

    Just one shot of Arexvy into the deltoid muscle of the upper arm is needed to protect people aged 60 years of age and older against lower respiratory tract disease (LRTD) caused by the respiratory syncytial virus (RSV). RSV season usually begins in October in the U.S., and people should get their shot before it starts. It is safe to get at the same time as a flu shot. It is not yet known if Arexvy will need to be given every year, like the flu shot. RSV does not mutate in the same way as influenza and SARS-CoV-2 do, so there shouldn’t be a need to update the vaccine or re-dose people every year, but more research is needed. Clinical trials reported protection for two RSV seasons, so it may only need to be given every two years.

    Arexvy has been shown in studies to lower the risk of developing respiratory syncytial virus (RSV)-associated lower respiratory tract disease by 82.6% and lowered the risk for severe disease by 94.1% in individuals 60 years of age and older.

    Arexvy may not work as well if you have a weakened immune system (if you are immunosuppressed). Tell your doctor if you have a weakened immune system or are taking treatment that weakens your immune system before you receive this vaccine.

    Arexvy and Abrysvo are both respiratory syncytial virus (RSV) vaccines that are approved for use in adults over the age of 60 to reduce their risk of developing lower respiratory tract disease (LRTD). Abrysvo is also approved for use in pregnant women between 32 through 36 weeks gestation, to protect infants against LRTD from the moment they are born until they are 6 months of age. Arexvy is made by GSK and was approved on May 3, 2023; the first RSV vaccine to be approved for older adults. Abrysvo is made by Pfizer and was approved on May 31, 2023; the second RSV vaccine to be approved for older adults. Continue reading

    Arexvy is not a live vaccine it is a recombinant subunit vaccine that does not contain any live virus. Recombinant vaccines are made by taking a small piece of DNA that codes for a specific protein (called an antigen) on the virus (in this case the respiratory syncytial virus [RSV]) and inserted into bacteria or yeast cells in a laboratory to manufacture the vaccine. The vaccine helps your body's immune system make proteins called antibodies against the virus. These antibodies will help prevent infection by attacking the virus if it ever infects your body.

    Arexvy is an adjuvanted recombinant subunit vaccine. To break this down: Adjuvanted – This means it contains a substance that helps to enhance the effects of the vaccine by boosting the response of the immune system Recombinant subunit – This means it is made by taking a small piece of DNA that codes for a specific protein (called an antigen) on the virus (in this case the respiratory syncytial virus [RSV]) and inserting it into bacteria or yeast cells in a laboratory to manufacture the vaccine. The vaccine helps your body's immune system make proteins called antibodies against the virus. These antibodies will help prevent infection by attacking the virus if it ever infects your body.

    Just one shot of Arexvy into the deltoid muscle of the upper arm is needed to protect people aged 60 years of age and older against lower respiratory tract disease (LRTD) caused by the respiratory syncytial virus (RSV). RSV season usually begins in October in the U.S., and people should get their shot before it starts. It is safe to get at the same time as a flu shot. It is not yet known if Arexvy will need to be given every year, like the flu shot. RSV does not mutate in the same way as influenza and SARS-CoV-2 do, so there shouldn’t be a need to update the vaccine or re-dose people every year, but more research is needed. Clinical trials reported protection for two RSV seasons, so it may only need to be given every two years.

    Arexvy has been shown in studies to lower the risk of developing respiratory syncytial virus (RSV)-associated lower respiratory tract disease by 82.6% and lowered the risk for severe disease by 94.1% in individuals 60 years of age and older.

    Arexvy may not work as well if you have a weakened immune system (if you are immunosuppressed). Tell your doctor if you have a weakened immune system or are taking treatment that weakens your immune system before you receive this vaccine.

    Arexvy and Abrysvo are both respiratory syncytial virus (RSV) vaccines that are approved for use in adults over the age of 60 to reduce their risk of developing lower respiratory tract disease (LRTD). Abrysvo is also approved for use in pregnant women between 32 through 36 weeks gestation, to protect infants against LRTD from the moment they are born until they are 6 months of age. Arexvy is made by GSK and was approved on May 3, 2023; the first RSV vaccine to be approved for older adults. Abrysvo is made by Pfizer and was approved on May 31, 2023; the second RSV vaccine to be approved for older adults. Continue reading

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords